Successful simplification of protease inhibitor-based HAART with triple nucleoside regimens in children vertically infected with HIV

AIDS

Volumn 21, Issue 18, 2007, Pages 2465-2472

  Palma, Paolo ^a,b   Romiti, Maria Luisa ^a   Cancrini, Caterina ^a,b   Pensieroso, Simone ^a   Montesano, Carla ^a   Santucci, Marilina B ^a   Bernardi, Stefania ^b   Martino, Alessandra M ^b   Rossi, Paolo ^a,b   Castelli Gattinara, Guido ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

Author keywords

CD8 T lymphocytes; HAART; HIV 1 infected children; Simplification; T cell V

Indexed keywords

ABACAVIR; ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; CD8 ANTIGEN; DIDANOSINE; INDINAVIR; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR; NELFINAVIR; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; T LYMPHOCYTE RECEPTOR BETA CHAIN; VIRUS RNA; ZIDOVUDINE;

ADOLESCENT; ADULT; ANTIGEN DETECTION; ARTICLE; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG FORMULATION; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSLIPIDEMIA; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERSENSITIVITY REACTION; IMMUNE DEFICIENCY; IMMUNOLOGY; IMMUNOREACTIVITY; LIPODYSTROPHY; METABOLIC DISORDER; PRIORITY JOURNAL; PROSPECTIVE STUDY; T LYMPHOCYTE ACTIVATION; TABLET; VERTICAL TRANSMISSION; VIRUS LOAD;

ADOLESCENT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD8-POSITIVE T-LYMPHOCYTES; CHILD; CHILD, PRESCHOOL; CHOLESTEROL; DISEASE TRANSMISSION, VERTICAL; EPIDEMIOLOGIC METHODS; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MALE; PATIENT COMPLIANCE; PROSPECTIVE STUDIES; RECEPTORS, ANTIGEN, T-CELL, ALPHA-BETA; REVERSE TRANSCRIPTASE INHIBITORS; TREATMENT OUTCOME; TRIGLYCERIDES;

EID: 36348957298     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAD.0b013e3282f1560b     Document Type: Article

References (47)

1. Gortmaker SL, Hughes M, Cervia J, Bradi M, Johnson GM, Seage GR 3rd, et al. Effect of combination therapy including protease inhibitors on mortality among children and adolescents infected with HIV-1. N Engl J Med 2001; 345:1522-1528.
2. de Martino M, Tovo PA, Balducci M, Galli L, Gabbiano C, Rezza G, et al. Reduction in mortality with availability of antiretroviral therapy for children with perinatal HIV-1 infection. Italian Register for HIV Infection in Children and the Italian National AIDS Registry. JAMA 2000; 284:190-197.
3. Giacomet V, Albano F, Starace F, de Franciscis A, Giaquinto C, Gattinara GC, et al. Adherence to antiretroviral therapy and its determinants in children with human immunodeficiency virus infection: a multicentre, national study. Acta Paediatr 2003; 92:1398-1402.
4. O'Brien ME, Clark RA, Besch CL, Myers L, Kissinger P. Patterns and correlates of discontinuation of the initial HAART regimen in an urban outpatient cohort. J Acquir Immune Defic Syndr 2003; 34:407-414.
5. Gibb DM, Goodall RL, Giacomet V, McGee L, Compagnucci A, Lyall H, et al. Adherence to prescribed antiretroviral therapy in human immunodeficiency virus-infected children in the PENTA 5 trial. Pediatr Infect Dis 2003; 22:56-62.
6. Vigano A, Mora S, Testolin C, Beccio S, Schneider L, Bricalli D, et al. Increased lipodystrophy is associated with increased exposure to highly active antiretroviral therapy in HIV-infected children. J Acquir Immune Defic Syndr 2003; 32:482-489.
7. Taylor P, Worrell C, Steinberg SM, Hazra R, Jankelevich S, Wood LV, et al. Natural history of lipid abnormalities and fat redistribution among human immunodeficiency virus-infected children receiving long-term, protease inhibitor-containing, highly active antiretroviral therapy regimens. Pediatrics 2004; 114:235-242.
8. Rhoads MP, Smith CJ, Tudor-Williams G. Effects of highly active antiretroviral therapy on paediatric metabolite levels. HIV Med 2006; 7:16-24.
9. McComsey GA, Leonard E. Metabolic complications of HIV therapy in children. AIDS 2004; 18:1753-1768.
10. Carter RJ, Wiener J, Abrams EJ, Farley J, Nesheim S, Palumbo P, et al. Dyslipidemia among perinatally HIV-infected children enrolled in the PACTS-HOPE cohort, 1999-2004: a longitudinal analysis. J Acquir Immune Defic Syndr 2006; 41:453-460.
11. Murphy RL, Smith WJ. Switch studies: a review. HIV Med 2002; 3:146-155.
12. Barreiro P, Garcia-Benayas T, Soriano V, Gallant J. Simplification of antiretroviral treatment: how to sustain success, reduce toxicity and ensure adherence avoiding PI use. AIDS Rev 2002; 4:233-241.
13. Negredo E, Bonjoch A, Clotet B. Benefits and concerns of simplification strategies in HIV-infected patients. J Antimicrob Chemother 2006; 58:235-242.
14. Opravil M, Baumann D, Chave JP, Furrer H, Calmy A, Bernasconi E, et al. Long-term efficacy after switching from protease inhibitor-containing highly active antiretroviral therapy to abacavir, lamivudine, and zidovudine. AIDS 2004; 18:2213-2215.
15. Bonjoch A, Paredes R, Galvez J, Miralles C, Videla S, Martinez E, et al. Antiretroviral treatment simplification with 3 NRTIs or 2 NRTIs plus nevirapine in HIV-1-infected patients treated with successful first-line HAART. J Acquir Immune Defic Synd 2005; 39:313-316.
16. Markowitz M, Hill-Zabala C, Lang J, DeJesus E, Liao Q, Lanier ER, et al. Induction with abacavir/lamivudine/zidovudine plus efavirenz for 48 weeks followed by 48-week maintenance with abacavir/lamivudine/zidovudine alone in antiretroviral-naive HIV-1-infected patients. J Acquir Immune Defic Syndr 2005; 39:257-264.
17. Arribas JR. The rise and fall of triple nucleoside reverse transcriptase inhibitor (NRTI) regimens. J Antimicrob Chemother 2004; 54:587-592.
18. Sharland M, Blanche S, Castelli G, Ramos J, Gibb DM. PENTA Steering Committee. PENTA guidelines for the use of antiretroviral therapy. HIV Med 2004; 5 (Suppl 2):61-86.
19. Christensen B, Glueck C, Kwiterovich P, Degroot I, Chase G, Heiss G, et al. Plasma cholesterol and triglyceride distributions in 13 665 children and adolescents: the Prevalence Study of the Lipid Research Clinics Program. Pediatr Res 1980; 14:194-202.
20. Romiti ML, Cancrini C, Castelli-Gattinara G, Di Cesare S, Ciaffi P, Bernardi S, et al. Kinetics of the T-cell receptor CD4 and CD8 V beta repertoire in HIV-1 vertically infected infants early treated with HAART. AIDS 2001; 15:2075-2084.
21. Amicosante M, Gioia C, Montesano C, Casetti R, Topino S, D'Offizi G, et al. Computer-based design of an HLA haplotype and HIV-clade independent cytotoxic T-lymphocyte assay for monitoring HIV-specific immunity. Mol Med 2002; 8:798-807.
22. Pensieroso P, Romiti ML, Palma P, Castelli-Gattinare G, Bernardi S, Freda E, et al. Switching from PI-based-HAART to PI-sparing regimen is associated with improved specific HIV-immune responses in HIV-infected children. AIDS 2006; 20:1893-1896.
23. Sarmati L, Parisi SG, Nicastri E, d'Ettorre G, Andreoni C, Dori L, et al. Cellular HIV-1 DNA quantitation in patients during simplification therapy with protease inhibitor-sparing regimens. J Med Virol 2007; 79:880-886.
24. Shearer WT, Rosenblatt HM, Gelman RS, Oyomopito R, Plaeger S, Stiehm ER, et al., Pediatric AIDS Clinical Trials Group. Lymphocyte subsets in healthy children from birth through 18 years of age: the Pediatric AIDS Clinical Trials Group P1009 study. J Allergy Clin Immunol 2003; 112:973-980.
25. Handforth J, Sharland M. Triple nucleoside reverse transcriptase inhibitor therapy in children. Paediatr Drugs 2004; 6:147-159.
26. Ruff CT, Ray SC, Kwon P, Zinn R, Pendleton A, Hutton N, et al. Persistence of wild-type virus and lack of temporal structure in the latent reservoir for human immunodeficiency virus type 1 in pediatric patients with extensive antiretroviral exposure. J Virol 2002; 76:9481-9492.
27. Pellegrin I, Caumont A, Garrigue I, Merel P, Schrive MH, Fleury H, et al. Predictive value of provirus load and DNA human immunodeficiency virus genotype for successful abacavir-based simplified therapy. J Infect Dis 2003; 187:38-46.
28. Re MC, Vitone F, Bon I, Schiavone P, Gibellini D. Meaning of DNA detection during the follow-up of HIV-1 infected patients: a brief review. New Microbiol 2006; 29:81-88.
29. Andre P, Groettrup M, Klenerman P, de Giuli R, Booth BL, Cerundolo V, et al. An inhibitor of HIV-1 protease modulates proteasome activity, antigen presentation, and T cell responses. Proc Natl Acad Sci USA 1998; 95:13120-13124.
30. Piccinini M, Rinaudo MT, Anselmino A, Buccinna B, Ramondetti C, Dematteis A, et al. The HIV protease inhibitors nelfinavir and saquinavir, but not a variety of HIV reverse transcriptase inhibitors, adversely affect human proteasome function. Antivir Ther 2005; 10:215-223.
31. Piccinini M, Rinaudo MT, Chiapello N, Ricotti E, Baldovino S, Mostert M, et al. The human 26S proteasome is a target of antiretroviral agents. AIDS 2002; 16:693-700.
32. Legrand FA, Abadi J, Jordan KA, Davenport MP, Deeks SG, Fennelly GJ, et al. Partial treatment interruption of protease inhibitors augments HIV-specific immune responses in vertically infected pediatric patients. AIDS 2005; 19:1575-1585.
33. Correa R, Harari A, Vallelian F, Resino S, Munoz-Fernandez MA, Pantaleo G. Functional patterns of HIV-1-specific CD4T-cell responses in children are influenced by the extent of virus suppression and exposure. AIDS 2007; 21:23-30.
34. Seder RA, Ahmed R. Similarities and differences in CD4+ and CD8+ effector and memory T cell generation. Nat Immunol 2003; 4:835-842.
35. Saez-Llorens X, Nelson RP Jr, Emmanuel P, Wiznia A, Mitchell C, Church JA, et al. A randomized, double-blind study of triple nucleoside therapy of abacavir, lamivudine, and zidovudine versus lamivudine and zidovudine in previously treated human immunodeficiency virus type 1-infected children. The CNAA3006 Study Team. Pediatrics 2001; 107:E4.
36. Paediatric European Network for Treatment of AIDS (PENTA). Comparison of dual nucleoside-analogue reverse-transcriptase inhibitor regimens with and without nelfinavir in children with HIV-1 who have not previously been treated: the PENTA 5 randomised trial. Lancet 2002; 359:733-740.
37. Leonard EG, McComsey GA. Metabolic complications of antiretroviral therapy in children. Pediatr Infect Dis J 2003; 22:77-84.
38. Katlama C, Fenske S, Gazzard B, Lazzarin A, Clumeck N, Mallolas J, et al. TRIZAL study: switching from successful HAART to Trizivir (abacavir-lamivudine-zidovudine combination tablet): 48 weeks efficacy, safety and adherence results. HIV Med 2003; 4:79-86.
39. Keiser PH, Sension MG, DeJesus E, Rodriguez A, Olliffe JF, Williams VC, et al. Substituting abacavir for hyperlipidemiaassociated protease inhibitors in HAART regimens improves fasting lipid profiles, maintains virologic suppression, and simplifies treatment. BMC Infect Dis 2005; 5:2.
40. Mc Comsey G, Bhumbra N, Ma JF, Rathore M, Alvarez A, First Pediatric Switch Study. Impact of protease inhibitor substitution with efavirenz in HIV-infected children: results of the First Pediatric Switch Study. Pediatrics 2003; 111:275-281.
41. Vigano A, Aldrovandi GM, Giacomet V, Merlo M, Martelli L, Beretta S, et al. Improvement in dyslipidaemia after switching stavudine to tenofovir and replacing protease inhibitors with efavirenz in HIV-infected children. Antivir Ther 2005; 10:917-924.
42. Lemieux I, Lamarche B, Couillard C, Pascot A, Cantin B, Bergeron J, et al. Total cholesterol/HDL cholesterol ratio vs LDL cholesterol/HDL cholesterol ratio as indices of ischemic heart disease risk in men: the Quebec Cardiovascular Study. Arch Intern Med 2001; 161:2685-2692.
43. Stein JH, Klein MA, Bellehumeur JL, McBride PE, Wiebe DA, Otvos JD, et al. Use of human immunodeficiency virus-1 protease inhibitors is associated with atherogenic lipoprotein changes and endothelial dysfunction. Circulation 2001; 104:257-262.
44. European Paediatric Lipodystrophy Group. Antiretroviral therapy, fat redistribution and hyperlipidemia in HIV-infected children in Europe. AIDS 2004; 18:1443-1451.
45. Farley J, Gona P, Crain M, Cervia J, Oleske J, Seage G, et al. Prevalence of elevated cholesterol and associated risk factors among perinatally HIV-infected children (4-19 years) in PACTG 219C. J Acquir Immune Defic Syndr 2005; 38:480-487.
46. Vigano A, Giacomet V. Nucleoside analogues toxicities related to mitochondrial dysfunction: focus on HIV-infected children. Antivir Ther 2005; 10 (Suppl 2):M53-M64.
47. Nolan D, Hammond E, James I, McKinnon E, Mallal S. Contribution of nucleoside-analogue reverse transcriptase inhibitor therapy to lipoatrophy from the population to the cellular level. Antivir Ther 2003; 8:617-626.